PharmaCyte Biotech Inc (PMCB)

[DragonBear]

PMCB un-likely up-listing (NASDAQ)

They do not qualify. See this

Post

1. More Directors. More Directors to pay.

2. Increase A/S to $50B to increase share dilution. Along with the potential of cranking up toxic debt notes.

3. To approve PharmaCyte’s 2021 Equity Incentive Plan to further enhance the wealth of insiders.

4.

to ratify PharmaCyte’s appointment of Armanino LLP...They probably need this accountant so they have one year of certified year end statements.

Every time they submit a 10K it needs an Armanino to sign off that it has been audited. Nothing new. Neither is Armanino new -been around since 2017.

Net result: PMCB wants to pay out to more BOD members. Raise the A/S up into the clouds at 50B, so they can massively dilute the shares, increase compensation, and keep Armanino around for another yr. Yippee!